Therapeutic Drug Monitoring Ranges for MRCP Part 1
- Crack Medicine
- 2 days ago
- 4 min read
TL;DR
List: Therapeutic Drug Monitoring (Ranges) is a frequently tested pharmacology topic in MRCP Part 1, especially when interpreting drug toxicity, treatment failure and renal impairment. Candidates should know which medicines require monitoring, the usual therapeutic ranges, when samples should be taken, and the common examination traps. This guide summarises the highest-yield drugs, provides an exam-style case, and finishes with a practical revision checklist.
Why this matters
MRCP Part 1 commonly assesses whether candidates can:
Identify drugs requiring routine monitoring.
Recall approximate therapeutic ranges.
Recognise toxicity despite apparently "normal" levels.
Understand the importance of sampling time.
Apply TDM principles in renal failure, liver disease and drug interactions.
The examination focuses more on clinical interpretation than pure memorisation.
Core Sections
What is Therapeutic Drug Monitoring?
Therapeutic Drug Monitoring refers to measuring drug concentrations in blood to ensure that:
concentrations remain within the therapeutic range,
toxicity is avoided,
treatment remains effective.
Not every medicine requires TDM.
Ideal drugs for monitoring usually have:
narrow therapeutic index,
significant pharmacokinetic variability,
poor correlation between dose and blood level,
measurable serum concentration,
serious toxicity.
High-yield therapeutic drug monitoring ranges
Drug | Typical therapeutic range* | Important exam points |
Digoxin | 0.5–2.0 ng/mL (often 0.5–0.9 preferred in heart failure) | Measure ≥6 hours after dose |
Lithium | 0.4–1.0 mmol/L (maintenance) | Toxicity often >1.5 mmol/L |
Phenytoin | 10–20 mg/L | Correct for hypoalbuminaemia |
Valproate | 50–100 mg/L (approximate) | Routine TDM less useful than clinical assessment |
Carbamazepine | 4–12 mg/L | Auto-induction affects levels |
Gentamicin | Peak/trough protocols vary | Trough monitoring commonly tested |
Vancomycin | Target trough depends on infection | Monitor renal function closely |
Theophylline | 10–20 mg/L | Toxicity increases >20 mg/L |
Ciclosporin | Target varies by indication | Numerous CYP interactions |
Tacrolimus | Target varies by transplant stage | Nephrotoxicity is common |
*Reference ranges vary slightly between laboratories.
The five most tested subtopics
1. Lithium monitoring
Lithium is one of the highest-yield drugs in MRCP Part 1.
Candidates should remember:
narrow therapeutic window,
renal excretion,
dehydration increases toxicity,
NSAIDs, ACE inhibitors and thiazides increase lithium concentration,
tremor, confusion and ataxia suggest toxicity.
Always interpret the level alongside:
renal function,
hydration,
timing of sample,
clinical symptoms.
2. Digoxin
Digoxin concentrations should not be checked immediately after administration because tissue distribution is incomplete.
Key points:
sample at least six hours after oral dose,
toxicity may occur with "therapeutic" concentrations,
hypokalaemia predisposes to toxicity,
renal impairment increases serum concentration.
Common examination findings include:
yellow vision,
nausea,
arrhythmias,
confusion.
3. Antiepileptic drugs
Phenytoin remains the classic MRCP drug for TDM.
Important facts:
highly protein bound,
hypoalbuminaemia increases free drug,
nonlinear (zero-order) pharmacokinetics,
small dose increases may produce large concentration changes.
Carbamazepine requires monitoring because:
hepatic enzyme auto-induction alters levels,
numerous CYP interactions,
toxicity includes diplopia and ataxia.
4. Aminoglycosides and vancomycin
Monitoring reduces nephrotoxicity and ototoxicity.
Remember:
renal impairment prolongs elimination,
trough levels are generally more clinically important than peak levels in many modern dosing strategies,
dosing intervals are adjusted according to renal function.
5. Immunosuppressants
Tacrolimus and ciclosporin require close monitoring because:
therapeutic window is narrow,
underdosing risks rejection,
overdosing causes nephrotoxicity,
CYP3A4 interactions are common.
Five common examination traps
Trap 1
Learning drug ranges without learning when to sample.
Timing is frequently tested.
Trap 2
Ignoring renal function.
Many monitored drugs are primarily renally excreted.
Trap 3
Assuming therapeutic concentration excludes toxicity.
Clinical findings always take precedence.
Trap 4
Forgetting protein binding.
Phenytoin concentrations are misleading in hypoalbuminaemia.
Trap 5
Memorising exact numbers without understanding principles.
MRCP usually rewards clinical interpretation more than isolated recall.
Numbered high-yield revision list
Lithium is entirely renally excreted.
Digoxin level should be checked at least six hours after dosing.
Phenytoin follows nonlinear kinetics.
Hypokalaemia worsens digoxin toxicity.
Carbamazepine induces hepatic enzymes.
Aminoglycosides require renal monitoring.
Tacrolimus commonly causes nephrotoxicity.
Ciclosporin interacts with many CYP inhibitors.
Clinical toxicity overrides laboratory values.
Always interpret drug levels alongside timing of blood sampling.
Practical examples / mini-cases
Mini-MCQ
A 70-year-old woman taking lithium for bipolar disorder develops vomiting and diarrhoea after gastroenteritis. Her GP prescribes ibuprofen for muscle pain. Two days later she develops coarse tremor, confusion and unsteady gait.
What is the most likely explanation?
A. Lithium resistance
B. Lithium toxicity
C. Serotonin syndrome
D. Neuroleptic malignant syndrome
E. Hyponatraemia alone
Correct answer: B. Lithium toxicity
Explanation
Dehydration reduces lithium clearance. NSAIDs further decrease renal lithium excretion, causing serum concentrations to rise rapidly. The combination of gastrointestinal illness, renal impairment and NSAID use is a classic MRCP scenario.
Practical study-tip checklist
Use this checklist during revision:
□ Learn which drugs require routine TDM.
□ Remember approximate—not laboratory-specific—therapeutic ranges.
□ Know when blood samples should be taken.
□ Recognise toxicity symptoms before laboratory confirmation.
□ Revise renal pharmacology alongside TDM.
□ Review important CYP450 drug interactions.
□ Practise interpretation using clinical scenarios.
□ Complete timed pharmacology questions in the Crack Medicine QBank.
□ Revisit difficult concepts using MRCP lectures:
FAQs
Which drugs are most commonly tested for therapeutic drug monitoring in MRCP Part 1?
Lithium, digoxin, phenytoin, carbamazepine, aminoglycosides, vancomycin, tacrolimus and ciclosporin are among the highest-yield medicines. Focus on why monitoring is required rather than memorising every laboratory value.
Is the exact therapeutic range always examined?
Usually not. MRCP Part 1 places greater emphasis on recognising toxicity, interpreting blood levels and understanding sampling time. Approximate therapeutic ranges are generally sufficient.
Why should digoxin levels be measured several hours after dosing?
Immediately after administration, digoxin is still distributing into tissues. Measuring too early can produce misleadingly high serum concentrations.
Does a therapeutic drug level exclude toxicity?
No. Clinical features always take priority. Toxicity may occur despite concentrations within the quoted therapeutic range, particularly in elderly patients or those with electrolyte disturbances.
What is the best way to revise therapeutic drug monitoring?
Combine concise notes with repeated MCQ practice and clinical cases. Revisiting pharmacokinetic principles alongside common drug interactions improves long-term retention.
Ready to start?
Therapeutic Drug Monitoring is a recurring pharmacology theme throughout MRCP Part 1. Mastering the principles behind monitoring is more valuable than memorising isolated numbers. Continue your preparation with the MRCP Part 1 overview, practise using the Free MRCP QBank, and consolidate difficult pharmacology topics through Crack Medicine lectures.
MRCP Part 1 Overview: https://www.crackmedicine.com/mrcp-part-1
Free MRCP QBank: https://www.crackmedicine.com/qbank
MRCP Lectures: https://www.crackmedicine.com/lectures
Sources
MRCP(UK). Examination information and curriculum. https://www.mrcpuk.org/
British National Formulary (BNF). https://bnf.nice.org.uk/
NICE Clinical Knowledge Summaries. https://cks.nice.org.uk/
MHRA Drug Safety Updates. https://www.gov.uk/drug-safety-update
Comments